Multi-organ protection during open heart surgery

Chinese Medical Journal

Volumn 114, Issue 1, 2001, Pages 3-8

  Wan, Song ^a   Yim, Anthony P C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Inflammatory response; Organ protection

Indexed keywords

APROTININ; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; CORTICOSTEROID; CYTOKINE; ENDOTOXIN; HEPARIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; NITRIC OXIDE; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA;

BIOCOMPATIBILITY; BRAIN PROTECTION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CORONARY ARTERY BYPASS SURGERY; HEART INJURY; HEART PROTECTION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; KIDNEY INJURY; NEUROLOGICAL COMPLICATION; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; REVIEW;

ADRENAL CORTEX HORMONES; APROTININ; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; CYTOKINES; HEPARIN; HUMANS; NITRIC OXIDE;

EID: 0035089562     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997;112:676-692.
2. Wan S, LeClerc JL, Vincent JL. Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann Thorac Surg 1997;63:269-276.
3. Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg 1998;66:2135-2144.
4. Boyle EM Jr, Kovacich JC, Hèbert CA, et al. Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. J Thorac Cardiovasc Surg 1998;116:114-121.
5. Wan S, Marchant A, DeSmet JM, et al. Human cytokine responses to cardiac transplantation and coronary artery bypass grafting. J Thorac Cardiovasc Surg 1996;111:469-477.
6. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96:3542-3548.
7. Wan S, LeClerc JL, Huynh CH, et al. Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass? J Thorac Cardiovasc Surg 1999;117:1004-1008.
8. Kelly JL, O' Sullivan C, O' Riordain M, et al. Is circulating endotoxin the trigger for the systemic inflammatory response syndrome seen after injury? Ann Surg 1997;225:530-543.
9. Bennett-Guerrerro E, Ayuso L, Hamilton-Davies C, et al. Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 1997;277:646-650.
10. Wan S, DeSmet JM, Barvais L, et al. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996;112:806-811.
11. Meldrum DR, Cleveland JC Jr, Cain BS, et al. Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfused model of cardiac ischemia-reperfusion injury. Ann Thorac Surg 1998;65:439-443.
12. Fransen E, Maessen J, Dentener M, et al. Systemic inflammation present in patients undergoing CABG without extracorporeal circulation. Chest 1998;113:1290-1295.
13. Wan S, Izzat MB, Lee TW, et al. Avoiding cardiopulmonary bypass in multivessel-CABG reduces cytokine response and myocardial injury. Ann Thorac Surg 1999;68:52-57.
14. Sekido N, Mukaida N, Harada A, et al. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993;365:654-657.
15. Hayward R, Nossuli TO, Scalia R, et al. Cardioprotective effect of interleukin-10 in murine myocardial ischemia-reperfusion. Eur J Pharmacol 1997;334:157-163.
16. Osman MO, Jacobsen NO, Kristensen JU, et al. IT 9302, a synthetic interleukin-10 agonist, diminishes acute lung injury in rabbits with acute necrotizing pancreatitis. Surgery 1998;124:584-592.
17. Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996;125:191-196.
18. Kawamura T, Inada K, Nara N, et al. Influence of methylprednisolone on cytokine balance during cardiac surgery. Crit Care Med 1999;27:545-548.
19. Wan S, LeClerc JL, Schmartz D, et al. Hepatic release of interleukin-10 during cardiopulmonary bypass in steroid-pretreated patients. Am Heart J 1997;133:335-339.
20. Kawamura T, Wakusawa R, Inada K. Interleukin-10 and interleukin-1 receptor antagonists increase during cardiac surgery. Can J Anaesth 1997;44:38-42.
21. Marie C, Muret J, Fitting C, et al. Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. Blood 1998;91:3439-3446.
22. Wan S, LeClerc JL, Antoine M, et al. Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study. Ann Thorac Surg 1999;68:1230-1235.
23. Plochl W, Liam BL, Cook DJ, et al. Cerebral response to haemodilution during cardiopulmonary bypass in dogs; the role of nitric oxide synthase. Br J Anaesth 1999;82:237-243.
24. Tseng EE, Brock MV, Lange MS, et al. Monosialoganglioside GMI inhibits neurotoxicity after hypothermic circulatory arrest. Surgery 1998;124:298-306.
25. Brett SJ, Quinlan GJ, Mitchell J, et al. Production of nitric oxide during surgery involving cardiopulmonary bypass. Crit Care Med 1998;26:272-278.
26. Beghetti M, Silkoff PE, Caramori M, et al. Decreased exhaled nitric oxide may be a marker of cardiopulmonary bypass-induced injury. Ann Thorac Surg 1998;66:532-534.
27. Mayers I, Salas E, Hurst T, et al. Increased nitric oxide synthase activity after canine cardiopulmonary bypass is suppressed by s-nitrosoglutathione. J Thorac Cardiovasc Surg 1999;117:1009-1016.
28. Massoudy P, Zahler S, Barankay A, et al. Sodium nitroprusside during coronary artery bypass grafting: evidence for an antiinflammatory action. Ann Thorac Surg 1999;67:1059-1064.
29. Chello M, Mastroroberto P, Marchese AR, et al. Nitric oxide inhibits neutrophil adhesion during experimental extracorporeal circulation. Anesthesiology 1998;89:443-448.
30. Champsaur G, Vedrinne C, Martinot S, et al. Flow-induced release of + endothelium-derived relaxing factor during pulsatile bypass: experimental study in the fetal lamb. J Thorac Cardiovasc Surg 1997;114:738-745.
31. Vedrinne C, Tronc F, Martinot S, et al. Effects of various flow types on maternal hemodynamics during fetal bypass: is there nitric oxide release during pulsatile perfusion? J Thorac Cardiovasc Surg 1998;116:432-439.
32. Chaney MA, Nikolov MP, Blakeman BP, et al. Hemodynamic effects of methylprednisolone in patients undergoing cardiac operation and early extubation. Ann Thorac Surg 1999;67:1006-1011.
33. Engelman RM, Rousou JA, Flack JE III , et al. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg 1995;60:801-804.
34. Wan S, DeSmet JM, Antoine M, et al. Steroid administration in heart and heart-lung transplantation: is the timing adequate? Ann Thorac Surg 1996;61:674-678.
35. Lodge AJ, Chai PJ, Daggett CW, et al. Methylprednisolone reduces the inflammatory response to cardiopulmonary bypass in neonatal piglets: timing of dose is important. J Thorac Cardiovasc Surg 1999;117:515-522.
36. Andersen LW, Baek L, Thomsen BS, et al. Effect of methylprednisolone on endotoxemia and complement activation during cardiac surgery. J Cardiothorac Anesth 1989;3:544-549.
37. Segel LD, Follette DM, Castellanos LM, et al. Steroid pretreatment improves graft recovery in a sheep orthotopic heart transplantation model. J Heart Lung Transplant 1997;16:371-380.
38. Diego RP, Mihalakakos PJ, Hexum TD, et al. Methylprednisolone and full-dose aprotinin reduce reperfusion injury after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:29-31.
39. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-253.
40. Lemmer JH Jr, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1659-668.
41. D' Ambra MN, Akins CW, Blackstone EH, et al. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 1996;112:1081-1089.
42. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236-2244.
43. Hayashida N, Isomura T, Sato T, et al. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg 1997;114:261-269.
44. Dietrich W, Schopf K, Spannagl M, et al. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations. Ann Thorac Surg 1998;65:70-78.
45. Carrel TP, Schwanda M, Vogt PR, et al. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998;66:153-158.
46. Gott JP, Cooper WA, Schmidt FE Jr, et al. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg 1998;66:747-754.
47. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998;116:716-730.
48. Bruda NL, Hurlbert BJ, Hill GE. Aprotinin reduces nitric oxide production in vitro and in vivo in a dose-dependent manner. Clin Sci (Colch) 1998;94:505-509.
49. Hill GE, Diego RP, Stammers AH, et al. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. Ann Thorac Surg 1998;65:66-69.
50. Tassani P, Richter JA, Barankay A, et al. Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures? J Cardiothorac Vasc Anesth 1999;13:165-172.
51. Bannan S, Martin PG. Aprotinin complements heparin bonding in an in vitro model of cardiopulmonary bypass. Br J Haematol 1998;101:455-461.
52. Wippermann CF, Schmid FX, Eberle B, et al. Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. Ann Thorac Surg 1999;67:173-176.
53. Segal H, Sheikh S, Kallis P, et al. Complement activation during major surgery: the effect of extracorporeal circuits and high-dose aprotinin. J Cardiothorac Vasc Anesth 1998;12:542-547.
54. Wildevuur CRH, Jansen PGM, Bezemer PD, et al. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits. Eur J Cardiothorac Surg 1997;11:616-623.
55. Ranucci M, Mazzucco A, Pessotto R, et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ann Thorac Surg 1999;67:994-1000.
56. McCarthy PM, Yared JPP, Foster RC, et al. A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations. Ann Thorac Surg 1999;67:1268-1273.
57. Gu YJ, Mariani MA, van Oeveren W, et al. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Ann Thorac Surg 1993;65:420-424.
58. Ascione R, Lloyd CT, Gomes WJ, et al. Beating versus arrested heart revascularization: evaluation of myocardial function in a prospective randomized study. Eur J Cardiothorac Surg 1999;15:685-690.
59. Anderson RE, Li TQ, Hindmarsh T, et al. Increased extracellular brain water after coronary artery bypass grafting is avoided by off-pump surgery. J Cardiothorac Vasc Anesth 1999;13:698-702.
60. Ascione R, Lloyd CT, Underwood MJ, et al. On-pump versus off-pump coronary revascularization: evaluation of renal function. Ann Thorac Surg 1999;68:493-498.